Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.

-- STK-012 is an <ALPHA>/<BETA> biased IL-2 designed to specifically stimulate antigen activated T cells -- Results from an ongoing Phase 1a/1b to be presented at SITC -- Company will also present new ...

Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.

Cruz announces that investors with losses related to MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) have opportunity to lead the securities fraud class action lawsuit. IF YOU ...

A naturally occurring metabolic compound, pyruvate, has been identified as a potent suppressor of inflammation in ulcerative ...

An artificial intelligence model predicts how brain immune cells react to RNA and DNA nanoparticles, helping scientists design safer and more effective nucleic acid therapies faster.

Emerging opportunities in the STAT Inhibitors market lie in targeting dysregulated STAT pathways, particularly STAT3 and STAT5, for cancers and inflammatory conditions. Novel drugs like Tvardi's ...

Researchers at Moffitt Cancer Center have developed a novel biomaterial-based system that induces the formation of tertiary lymphoid-like structures, or TLSs. These immune cell clusters are ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a predominant chronic liver condition globally, intricately linked with ...

The lab-made 3D liver model serves as a human relevant platform for analyzing the progressive stages of the liver disease, ...

NEW YORK, Oct. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...